221 related articles for article (PubMed ID: 9767516)
21. Recurrent Pneumocystis carinii colonization in a heart-lung transplant recipient on long-term trimethoprim-sulfamethoxazole prophylaxis.
Faul JL; Akindipe OA; Berry GJ; Doyle RL; Theodore J
J Heart Lung Transplant; 1999 Apr; 18(4):384-7. PubMed ID: 10226906
[TBL] [Abstract][Full Text] [Related]
22. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
[TBL] [Abstract][Full Text] [Related]
24. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
Beumont MG; Graziani A; Ubel PA; MacGregor RR
Am J Med; 1996 Jun; 100(6):611-6. PubMed ID: 8678080
[TBL] [Abstract][Full Text] [Related]
25. Pneumocystis carinii pneumonia prophylaxis and early clinical manifestations of severe perinatal human immunodeficiency virus type 1 infection. Northern California Pediatric HIV Consortium.
Maldonado YA; Araneta RG; Hersh AL
Pediatr Infect Dis J; 1998 May; 17(5):398-402. PubMed ID: 9613653
[TBL] [Abstract][Full Text] [Related]
26. A case of pneumocystis pneumonia after cessation of secondary prophylaxis.
Quah SP; McBride M
Int J STD AIDS; 2001 Feb; 12(2):126-7. PubMed ID: 11236102
[TBL] [Abstract][Full Text] [Related]
27. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
28. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
Edge MD; Rimland D
AIDS; 1999 May; 13(8):991-2. PubMed ID: 10371182
[No Abstract] [Full Text] [Related]
29. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.
Kofteridis DP; Valachis A; Velegraki M; Antoniou M; Christofaki M; Vrentzos GE; Andrianaki AM; Samonis G
J Infect Chemother; 2014 Jul; 20(7):412-6. PubMed ID: 24767467
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group.
Walmsley SL; Khorasheh S; Singer J; Djurdjev O
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):498-505. PubMed ID: 9859964
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate and trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis.
Yamazaki H; Nanki T; Miyasaka N; Harigai M
J Rheumatol; 2011 Apr; 38(4):777; author reply 778. PubMed ID: 21459958
[No Abstract] [Full Text] [Related]
32. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.
Katsuyama T; Saito K; Kubo S; Nawata M; Tanaka Y
Arthritis Res Ther; 2014 Feb; 16(1):R43. PubMed ID: 24495443
[TBL] [Abstract][Full Text] [Related]
33. Pneumocystis carinii pneumonia after cessation of secondary prophylaxis in a patient on highly active antiretroviral therapy with a CD4 cell count greater than 200/mm3.
Lim L ; Street AC; Lewin SR
AIDS; 2001 Sep; 15(14):1912-3. PubMed ID: 11579267
[No Abstract] [Full Text] [Related]
34. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients.
Saukkonen K; Garland R; Koziel H
Chest; 1996 May; 109(5):1250-5. PubMed ID: 8625676
[TBL] [Abstract][Full Text] [Related]
35. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
Souza JP; Boeckh M; Gooley TA; Flowers ME; Crawford SW
Clin Infect Dis; 1999 Dec; 29(6):1467-71. PubMed ID: 10585797
[TBL] [Abstract][Full Text] [Related]
36. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
37. Pneumocystis pneumonia in children receiving chemotherapy.
Prasad P; Nania JJ; Shankar SM
Pediatr Blood Cancer; 2008 Apr; 50(4):896-8. PubMed ID: 17458875
[TBL] [Abstract][Full Text] [Related]
38. Successful desensitization to dapsone for Pneumocystis carinii prophylaxis in an HIV-positive patient.
Cook DE; Kossey JL
Ann Pharmacother; 1998 Dec; 32(12):1302-5. PubMed ID: 9876811
[TBL] [Abstract][Full Text] [Related]
39. Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.
Brun-Pascaud M; Fay M; Zhong M; Bauchet J; Dux-Guyot A; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Feb; 36(2):470-2. PubMed ID: 1605613
[TBL] [Abstract][Full Text] [Related]
40. Methemoglobinemia induced by trimethoprim-sulfamethoxazole in a patient with systemic lupus erythematosus.
Kawasumi H; Tanaka E; Hoshi D; Kawaguchi Y; Yamanaka H
Intern Med; 2013; 52(15):1741-3. PubMed ID: 23903510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
